Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAura Renew Acq Regulatory News (ARA)

Share Price Information for Aura Renew Acq (ARA)

Share Price is delayed by 15 minutes
Get Live Data
2.50    0.00 (0.00%)
Bid:
1.50
Ask:
3.50
Spread: 2.00 (133.333%)
Market Cap: £262.50k
ARA Live PriceLast checked at - London Stock Exchange

Intraday Aura Renew Acq Share Chart

Additional Listing

3 May 2006 15:26

Ardana PLC03 May 2006 3 May 2006 BLOCK LISTING Edinburgh, UK, 03 May 2006; Ardana plc (LSE:ARA) the emerging pharmaceuticalcompany focused on improving human reproductive health, today announces thatapplication has been made to the UK Listing Authority and the London StockExchange for a block listing of 2,494,967 ordinary shares of 1 (one) pence each. The application is in respect of shares to be allotted pursuant to theexercise of options under the Ardana Bioscience Employees' share option scheme,Ardana Ltd Employees' share option scheme and certain individual optionagreements between Ardana plc and non-executive directors and non-employees. For more information contact: ArdanaMaureen Lindsay Tel: + 44 (0) 131 226 8550 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $23.8billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andout-licensing to maintain a robust pipeline. Ardana's four lead products are summarised below: â€Ē StriantTM SR, a testosterone replacement therapy for which Ardana has marketing rights in Europe, has already been launched by Ardana through its own sales force in the UK as a treatment for men with confirmed hypogonadism â€Ē Teverelix LA, in development for three initial indications: prostate cancer and benign prostatic hyperplasia (both indications are at the phase II stage), and endometriosis (currently in phase I) â€Ē Testo Cream, a transdermal testosterone delivery system in phase II for the treatment of male hypogonadism â€Ē Invicorp(R), an injectable combination drug treatment for erectile dysfunction, already approved in Denmark and for which Ardana has marketing and manufacturing rights in Europe. Launch is expected in H2 2006 In addition, Ardana has a strong portfolio of follow-on products in development.Ardana completed its IPO on the London Stock Exchange in March 2005 raisingÂĢ21 million. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Apr 20072:41 pmRNSHolding(s) in Company
21st Mar 20073:00 pmRNSHolding(s) in Company
19th Mar 20076:21 pmRNSHolding(s) in Company
13th Mar 200712:00 pmRNSHolding(s) in Company
28th Feb 20072:58 pmRNSVoting Rights
14th Feb 20077:00 amRNSResearch Update
13th Feb 20077:01 amRNSRe Agreement
21st Dec 20067:00 amRNSTotal Voting Rights
19th Dec 20067:01 amRNSProduct Launch
19th Dec 20067:01 amRNSResearch Update
19th Dec 20067:01 amRNSInterim Results
12th Dec 20067:01 amRNSNotice of Results
16th Nov 20067:01 amRNSProduct Launch
2nd Nov 20062:09 pmRNSBlocklisting Interim Review
20th Oct 20065:37 pmRNSHolding(s) in Company
19th Oct 20063:10 pmRNSHolding(s) in Company
16th Oct 20065:40 pmRNSHolding(s) in Company
13th Oct 200610:34 amRNSDirector/PDMR Shareholding
12th Oct 20061:33 pmRNSEGM Statement
12th Oct 20067:46 amRNSResult of Placing
11th Oct 20061:51 pmRNSAGM Statement
28th Sep 200611:16 amRNSAnnual Information Update
20th Sep 20067:03 amRNSIssue of Equity
13th Sep 200611:40 amRNSAnnual Report and Accounts
11th Sep 20067:01 amRNSResearch Update
7th Sep 20067:02 amRNSResearch Update
31st Aug 20067:01 amRNSUS Patent for Teverelix LA
29th Jun 20067:02 amRNSFinal Results
29th Jun 20067:01 amRNSNon-Executive Director
14th Jun 20064:44 pmRNSNotice of Results
16th May 20064:17 pmRNSHolding(s) in Company
12th May 200612:19 pmRNSHolding(s) in Company
3rd May 20063:26 pmRNSAdditional Listing
12th Apr 20067:01 amRNSResearch Update
17th Mar 20067:02 amRNSAppointment
16th Mar 20063:10 pmRNSHolding(s) in Company
14th Mar 20065:41 pmRNSHolding(s) in Company
31st Jan 20067:01 amRNSFDA Update
13th Dec 20057:00 amRNSInterim Results
9th Nov 20057:00 amRNSRe Agreement
31st Oct 20057:00 amRNSResearch Update
28th Oct 20059:47 amRNSHolding(s) in Company
5th Oct 20057:00 amRNSStriant Germany Launch
27th Sep 20051:31 pmRNSHolding(s) in Company
21st Sep 200512:30 pmRNSDirector/PDMR Shareholding
21st Sep 20057:00 amRNSResearch Update
30th Aug 20057:00 amRNSChange of Adviser
29th Jun 20057:00 amRNSFinal Results
17th Jun 20057:58 amRNSNon-executive appointment
16th Jun 20057:01 amRNSRe Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.